Marie Komárková , Martin Benešík , Tereza Procházková , Adam Vinco , Monika Laichmanová , Soňa Smetanová , Petr Jelínek , Marek Moša , Tibor Botka , Miroslav Šoóš , Roman Pantůček
{"title":"抗菌防腐剂与Pbunavirus和Kayvirus属治疗性噬菌体的相容性","authors":"Marie Komárková , Martin Benešík , Tereza Procházková , Adam Vinco , Monika Laichmanová , Soňa Smetanová , Petr Jelínek , Marek Moša , Tibor Botka , Miroslav Šoóš , Roman Pantůček","doi":"10.1016/j.ejpb.2025.114781","DOIUrl":null,"url":null,"abstract":"<div><div>Implementing bacteriophages into dosage forms is a significant step for the practical application of phage therapy. While designing a dosage form, bacteriophages as active ingredients may be exposed to excipients, guaranteeing microbial quality. However, only a few antimicrobial preservatives have been studied regarding their interaction with bacteriophages during long-term storage. Here, the stability of the staphylococcal <em>Kayvirus</em> and pseudomonal <em>Pbunavirus</em> with twelve commonly used preservatives was monitored for thirteen weeks to assess the risk of destabilisation of phage suspensions by excipients. The effectiveness of preservatives on the test bacteria, yeast and mould was determined using a microdilution method and the phage lytic activity by plaque enumeration. The antimicrobial activity of preservatives with bacteriophages was confirmed, except benzalkonium chloride and chlorhexidine digluconate, which showed precipitation and were classified as incompatible. A complete loss of phage potency in both tested phages occurred with diazolidinyl urea and in <em>Kayvirus</em> with benzalkonium chloride. For both phages, a slight decrease in titer, by one order of magnitude, was observed with m-cresol, sodium propionate, sodium benzoate, and phenylethyl alcohol. For <em>Kayvirus</em>, thimerosal, parabens, and mono propylene glycol and for <em>Pbunavirus</em>, phenoxyethanol also met the criteria. The decrease by two or more orders was determined for the remaining cases. This study helps select antimicrobial preservatives for optimizing dosage formulations with the therapeutically applicable bacteriophages.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"214 ","pages":"Article 114781"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Compatibility of antimicrobial preservatives with therapeutic bacteriophages of the genera Pbunavirus and Kayvirus\",\"authors\":\"Marie Komárková , Martin Benešík , Tereza Procházková , Adam Vinco , Monika Laichmanová , Soňa Smetanová , Petr Jelínek , Marek Moša , Tibor Botka , Miroslav Šoóš , Roman Pantůček\",\"doi\":\"10.1016/j.ejpb.2025.114781\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Implementing bacteriophages into dosage forms is a significant step for the practical application of phage therapy. While designing a dosage form, bacteriophages as active ingredients may be exposed to excipients, guaranteeing microbial quality. However, only a few antimicrobial preservatives have been studied regarding their interaction with bacteriophages during long-term storage. Here, the stability of the staphylococcal <em>Kayvirus</em> and pseudomonal <em>Pbunavirus</em> with twelve commonly used preservatives was monitored for thirteen weeks to assess the risk of destabilisation of phage suspensions by excipients. The effectiveness of preservatives on the test bacteria, yeast and mould was determined using a microdilution method and the phage lytic activity by plaque enumeration. The antimicrobial activity of preservatives with bacteriophages was confirmed, except benzalkonium chloride and chlorhexidine digluconate, which showed precipitation and were classified as incompatible. A complete loss of phage potency in both tested phages occurred with diazolidinyl urea and in <em>Kayvirus</em> with benzalkonium chloride. For both phages, a slight decrease in titer, by one order of magnitude, was observed with m-cresol, sodium propionate, sodium benzoate, and phenylethyl alcohol. For <em>Kayvirus</em>, thimerosal, parabens, and mono propylene glycol and for <em>Pbunavirus</em>, phenoxyethanol also met the criteria. The decrease by two or more orders was determined for the remaining cases. This study helps select antimicrobial preservatives for optimizing dosage formulations with the therapeutically applicable bacteriophages.</div></div>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\"214 \",\"pages\":\"Article 114781\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0939641125001584\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125001584","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Compatibility of antimicrobial preservatives with therapeutic bacteriophages of the genera Pbunavirus and Kayvirus
Implementing bacteriophages into dosage forms is a significant step for the practical application of phage therapy. While designing a dosage form, bacteriophages as active ingredients may be exposed to excipients, guaranteeing microbial quality. However, only a few antimicrobial preservatives have been studied regarding their interaction with bacteriophages during long-term storage. Here, the stability of the staphylococcal Kayvirus and pseudomonal Pbunavirus with twelve commonly used preservatives was monitored for thirteen weeks to assess the risk of destabilisation of phage suspensions by excipients. The effectiveness of preservatives on the test bacteria, yeast and mould was determined using a microdilution method and the phage lytic activity by plaque enumeration. The antimicrobial activity of preservatives with bacteriophages was confirmed, except benzalkonium chloride and chlorhexidine digluconate, which showed precipitation and were classified as incompatible. A complete loss of phage potency in both tested phages occurred with diazolidinyl urea and in Kayvirus with benzalkonium chloride. For both phages, a slight decrease in titer, by one order of magnitude, was observed with m-cresol, sodium propionate, sodium benzoate, and phenylethyl alcohol. For Kayvirus, thimerosal, parabens, and mono propylene glycol and for Pbunavirus, phenoxyethanol also met the criteria. The decrease by two or more orders was determined for the remaining cases. This study helps select antimicrobial preservatives for optimizing dosage formulations with the therapeutically applicable bacteriophages.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.